• Home
• Kilas Global
• Jacobson Pharma and Yunnan Baiyao Group to Continue Exploring Further Possibilities of Business Cooperation and Other Collaborations

Kamis, 09 Mei 2019 09:58:00

Jacobson Pharma and Yunnan Baiyao Group to Continue Exploring Further Possibilities of Business Cooperation and Other Collaborations

HONG KONG, CHINA, - 8 May 2019 - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has been informed by Yunnan Baiyao Holdings Company Limited1 (雲南白藥控股有限公司) ("Baiyao Holdings") and Yunnan Baiyao Group Co.,Ltd.[1] (雲南白藥集團股份有限公司) ("Yunnan Baiyao Group") that Baiyao Holdings will be merged into and absorbed by Yunnan Baiyao Group.

Currently, Baiyao Holdings holds 200,000,000 shares of Jacobson Pharma, representing approximately 9.92% of the total number of the Group's issued shares.

Upon completion of the merger, such 200,000,000 shares are to be held by Yunnan Baiyao Group as the merged entity. Yunnan Baiyao Group is also to actively accelerate exploring potential business cooperation as stated in the letter of intent previously agreed with Jacobson Pharma.
 
Yunnan Baiyao Group is a renowned and respected brand and a leading company which has developed 16 pharmaceutical dosage forms with more than 370 products. The company initiated the merger proposal in October 2018 which was approved by the China Securities Regulatory Commission in late April 2019, approving it to issue shares as it absorbs Yunnan Baiyao. After the completion of the merger, Yunnan Baiyao Group's operating income is expected to grow to more than RMB27 billion.

With its strong financial strength, Yunnan Baiyao Group could leverage its brand, channel and medical resources through in-licensing, strategic cooperation, new product development as well as mergers and acquisitions to fuel business expansion and reinforce competitive strengths.
 
Jacobson Pharma has pre-eminent leadership in generics, specialty drugs and proprietary medicines in the industry. Backed by a vertically-integrated value chain and advanced production facilities, and bolstered by its robust product portfolio, the Group has one of the most extensive sales and distribution networks covering both the private and public market sectors in Hong Kong.

Meanwhile, with Hong Kong as its base, Jacobson Pharma has set to expand its regional platform and is poised to strategically collaborate with reputable manufacturers globally for establishing footholds in Asia Pacific including China, Korea, Japan, Taiwan, Singapore, Malaysia, Cambodia, Myanmar, Thailand and Vietnam.
 
Jacobson Pharma has previously entered into a letter of intent with Baiyao Holdings pursuant to which the parties agreed to conduct feasibility studies on possible business cooperation and other collaborations. In the future, the Group will continue to actively examine such further possibilities with Baiyao Holdings to broaden and deepen its market coverage in China and Asia Pacific in forging a competitive regional commercial platform aiming to  deliver sustainable values for shareholders. (*).

5 tahun lalu

Jacobson Pharma Announces FY2020 Interim Results

Profit Attributable to Shareholders Lifted by 30.5%
Portfolio and Market Expansion to Harness Growth Potentials
 
HONG KONG, - 26 November 2019 - Jacobson Pharma C

5 tahun lalu

Jacobson Pharma Launches Smartfish Health Nutrition Products from Norway in Greater China and Asia Pacific Region

HONG KONG, RIAUONE.com - 12 November 2019 - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the  "Group"; Stock Code: 2633), a leading company engaging in researc

5 tahun lalu

Jacobson Pharma Announces FY2019 Annual Results

Profit Attributable to Shareholders Increased by 23.9% to a Record High of HK$250.6 Million; Total Dividend Up 18.4% to HK4.5 Cents per Share

HONG KONG, CHINA, - 25 June 2

6 tahun lalu

Jacobson Pharma Announces FY2019 Interim Results

Profit from Operations Leapt by 40.7% to HK$158.6 Million

Declares Interim Dividend of HK1.5 cents per share

Growth Strategies to Tap Innovative Pharma Market and Ex